3-(piperazinylpropyl)indoles: Selective, orally bioavailable h5-HT(1D) receptor agonists as potential antimigraine agents

Journal of Medicinal Chemistry

Volumn 42, Issue 4, 1999, Pages 691-705

  Chambers, Mark S ^a   Street, Leslie J ^a   Goodacre, Simon ^a   Hobbs, Sarah C ^a   Hunt, Peter ^a   Jelley, Richard A ^a   Matassa, Victor G ^a   Reeve, Austin J ^a   Sternfeld, Francine ^a   Beer, Margaret S ^a   Stanton, Josephine A ^a   Rathbone, Denise ^a   Watt, Alan P ^a   MacLeod, Angus M ^a  

^a NEUROSCIENCE RESEARCH CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 (3 FLUOROPHENYL)ETHYL] 4 [3 [5 (1,2,4 TRIAZOL 4 YL) 1H INDOL 3 YL]PROPYL]PIPERAZINE; 3 (PIPERAZINYLPROPYL)INDOLE DERIVATIVE; ANTIMIGRAINE AGENT; ELETRIPTAN; NARATRIPTAN; RIZATRIPTAN; SEROTONIN 1D AGONIST; SUMATRIPTAN; UNCLASSIFIED DRUG; ZOLMITRIPTAN;

ANIMAL CELL; ARTICLE; CHO CELL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; NONHUMAN; STRUCTURE ANALYSIS;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CHO CELLS; CRICETINAE; INDOLES; MALE; MIGRAINE DISORDERS; MODELS, MOLECULAR; PIPERAZINES; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT1B; RECEPTOR, SEROTONIN, 5-HT1D; RECEPTORS, SEROTONIN; RECOMBINANT PROTEINS; SEROTONIN AGONISTS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0033602138     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm980569z     Document Type: Article

References (42)

1. (a) Ferrari, M. D. Sumatriptan in the treatment of migraine. Neurology 1993, 43 (Suppl. 3), S43-S47.
2. (b) Plosker, G. L.; McTavish, D. Sumatriptan, A reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs 1994, 47, 622-651.
3. Hoyer, D.; Bell, G. I.; Berelowitz, M.; Epelbaum, J.; Feniuk, W.; Humphrey, P. P. A.; O'Carroll, A. M.; Patel, Y. C.; Schonbrunn, A. Classification and nomenclature of serotonin receptors. Trends Pharmacol. Sci. 1995, 16, 86-88.
4. 1Dβ receptors. Eur. J. Pharmacol. 1995, 287, 79-84.
5. 1Dβ, respectively; see: Hoyer, D.; Martin, G. 5-HT receptor classification and nomenclature: towards a harmonization with the human genome. Neuropharmacology 1997, 36, 419-428.
6. 1D receptors: Pharmacology and therapeutic potential. Serotonin 1996, 1, 19-29.
7. 3H]-alniditan. Mol. Pharmacol. 1996, 50, 1567-1580.
8. 1B receptor-mediated responses in stably transfected C6-glial cells by ketanserin and GR 127,935. Eur. J. Pharmacol. 1996, 300, 141-145.
9. (c) Migraine: Pharmacology and Genetics; Sandler, M., Ferrari, M., Harnett, S., Eds.; Chapman and Hall: London, 1996.
10. 1 receptor subtype coupled to the inhibition of adenylate cyclase. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 408-412.
11. 1F-receptor agonists for the treatment of migraine. Eur. Pat. Appl. EP 0705600.
12. Overshiner, C. C.; Adham, N.; Zgombick, J. M.; Brancheck, T. A.; Calligaro, D. O.; Phebus, J. A. LY334370 is selective for the cloned 5-HT1F receptor. Poster presentation 528,12 at the 26th Annual Meeting Society for Neuroscience, Washington, D.C., November 1996.
13. Ottervanger, J. P.; van Witsen, T. B.; Valkenburg, H. A.; Grobbee, D. E.; Stricker, B. H. Adverse reactions attributed to Sumatriptan. A postmarketing study in general practice. Eur. J. Clin. Pharmacol. 1994, 41, 305-309.
14. Ferro, A.; Longmore, J.; Hill, R. G.; Brown, M. J. A comparison of the contractile effects of 5-hydroxytryptamine, Sumatriptan and MK-462 on human coronary artery in vitro. Br. J. Clin. Pharmacol. 1995, 40, 245-251.
15. (a) Bax, W. A.; Renzenbrink, G. J.; Van Heuven-Nolsen, D.; Thijssen, E. J. M.; Bos, E.; Saxena, P. R. 5-HT receptors mediating contractions of isolated human coronary artery. Eur. J. Pharmacol. 1993, 239, 203-210.
16. 1Dβ receptors. Circulation 1994, 90, 1141-1153.
17. Ottervanger, J. P.; Stricker, B. H. Ch. Cardiovascular adverse reactions to Sumatriptan. Cause for concern? CNS Drugs 1995, 3 (2), 90-98.
18. (a) Ferrari, M. D.; Saxena, P. R. Clinical and experimental effects of Sumatriptan in humans. Trends Pharmacol. Sci. 1993, 14, 129-133.
19. (b) Moskowitz, M. A. Neurogenic inflammation in the pathophysiology and treatment of migraine. Neurology 1993, 43 (Suppl. 3), S16-S20.
20. 1B/1D agonists: Structure-activity relationship and preclinical pharmacological distinctions. Curr. Med. Chem. 1997, 4, 295-312.
21. Bouchelet, I.; Cohen, Z.; Case, B.; Seguela, P.; Hamel, E. Differential expression of sumatriptan-sensitive 5-hydroxytryptamine receptors in human trigeminal ganglia and cerebral blood vessels. Mol. Pharmacol. 1996, 50, 219-223.
22. 1D receptors. J. Med. Chem. 1995, 38, 1799-1810.
23. 1B subtype. J. Med. Chem. 1997, 40, 3497-3500.
24. 1D receptor agonists as potential antimigraine agents. J. Med. Chem. 1997, 40, 3501-3503.
25. (a) Ihara, M.; Takahashi, T.; Shimizu, N.; Ishida, Y.; Sudow, I.; Fukumoto, K.; Kametani, T. Chiral construction of the estrane ring system by an intramolecular double michael reaction. J. Chem. Soc., Perkin Trans, 1 1989, 529-535.
26. (b) Ihara, M.; Suzuki, S.; Taniguchi, N.; Fukumoto, K. Deconjugation of α,β-unsaturated esters and an intramolecular michael reaction of bis-α,β-unsaturated esters with trialkylsilyl trifluoromethane-sulfonate in the presence of tertiary amine: Synthesis of (±)-Ricciocarpin A. J. Chem. Soc., Perkin Trans. 1 1993, 2251-2258.
27. 1D receptor agonist. J. Org. Chem. 1997, 62, 9192-9202.
28. (c) Grotjahn, D. B.; Andersen, N. H. Carbocyclizations employing 2-silyl-1,3-dithians. J. Chem. Soc. Chem. Commun. 1981, 306-307.
29. Sternfeld, F.; Baker, R.; Broughton, H. B.; Guiblin, A. R.; Jelley, R. A.; Matassa, V. G.; Reeve, A. J.; Beer, M. S.; Stanton, J. A.; Hargreaves, R. J.; Shepheard, S. L.; Longmore, J.; Razzaque, Z.; Graham, M. I.; Sohal, B.; Street, L. J. The chemical evolution of N,N-dimethyl-2-[5-(1,2,4-triazol-4-yl)-1H-indol-3-yl]ethylamine (L-741,604) and analogues: Potent and selective agonists for 5-HTiD receptors. Bioorg. Med. Chem. Lett. 1996, 6, 1825-1830.
30. Bernotas, R. C.; Adams, G. Synthesis of a 1-benzylpiperazin-2-one nitrone and its reaction with alkynes and alkenes. Tetrahedron Lett. 1996, 37 (41), 7339-7342.
31. Kane, J. M.; Carr, A. A. Alkylation of protected piperazinone dianions. Tetrahedron Lett. 1980, 21, 3019-3020.
32. 1D receptor subtype. Mol. Pharmacol. 1992, 42, 439-444.
33. 35S]GTPγS is resistant to this GTPase, it accumulates in the membrane and can be measured by virtue of its radiolabel. See, for example, ref 24.
34. 35S]GTPγS binding mediated by human muscarinic m1-m4 receptors: Antagonist studies. Br. J. Pharmacol. 1993, 109, 1120-1127.
35. Inflammation of the dura in animals, induced by electrical stimulation of the trigeminal ganglion, has been proposed as a possible model of migraine in humans; see: Buzzi, M. G.; Bonamini, M.; Moskowitz, M. A. Neurogenic model of migraine. Cephalgia 1995, 15, 277-280.
36. 50 130 nM; maximal efficacy 101% relative to 5-HT).
37. 1D receptor can be found in the Supporting Information.
38. Hunt, P.; McAllister, G.; Sinclair, H. A. Unpublished results.
39. 50 440 nM; maximal efficacy 71% relative to 5-HT).
40. Elliot, M.; Farnham, A. W.; Janes, N. F.; Johnson, D. M.; Pulman, D. A. Synthesis and insecticidal activity of lipophilic amides. Part 4: The effect of substituents on the phenyl group of 6-phenylhexa-2,4-dienamides. Pestic. Sci. 1987, 18 (4), 223-228.
41. (a) Beylin, V. G.; Goel, O. P. A convenient synthesis of tert-butyl N-(2-bromoethyl) carbamate. Org. Prep. Proced. Int. 1987, 19 (1), 78-80.
42. (b) Vedejs, E.; Stults, J. S. Synthesis of azocine derivatives from thioaldehyde Diels-Alder adducts. J. Org. Chem. 1988, 53, 2226-2232.